Droit des fondations d'utilité publique

Published: 1 June 2021

Les fondations d’utilité publique ne cessent de gagner en importance en Suisse et à l’étranger. Elles contribuent de manière essentielle à l’intérêt général dans de nombreux domaines comme l’aide humanitaire, l’art, l’assistance en cas de catastrophe, la culture, l’éducation, l’environnement, la protection des droits humains, la recherche scientifique, la santé ou la sécurité.

Cet ouvrage propose une étude pluridisciplinaire des règles de droit civil, administratif et fiscal applicables aux fondations d’utilité publique établies en Suisse. Il reflète l’état du droit au 1er janvier 2021 et rend compte des principales évolutions de la législation, de la jurisprudence et de la doctrine en la matière. L’ouvrage accorde une attention particulière aux questions qui concernent les fondations suisses poursuivant des buts d’utilité publique non seulement en Suisse mais également voire exclusivement à l’étranger.

Destiné aux étudiants, ce précis a pour but de les initier aux notions juridiques indispensables à la compréhension de la matière. Il a également pour vocation de servir de référence aux praticiens du droit des fondations et aux personnes occupant des fonctions au sein de fondations d’utilité publique.

Insights

Insights 04.08.2026

Switzerland steps up: Federal Patent Court affirms cross-border reach in patent litigation

Switzerland steps up: Federal Patent Court affirms cross-border reach in…

<p><strong>Switzerland as a forum for cross-border patent enforcement: the Federal Patent Court confirms its reach</strong></p> <p class="MsoBodyText">In a landmark decision of 17 July 2026 (S2025_003), the Swiss Federal Patent Court has sent a clear signal: Switzerland is very much in the game when it comes to cross-border patent enforcement. The Court confirmed that claims for infringement of foreign patent designations can be heard at the defendant’s Swiss domicile and established a powerful principle of parallel infringement analysis across all EPC member states. For patent holders pursuing multi-jurisdictional strategies, Switzerland must be on the map.</p> <p class="MsoBodyText">The case arose from interim proceedings brought by Regeneron Pharmaceuticals, Inc., Bayer HealthCare LLC and Bayer Consumer Care AG against Sandoz Group AG, Sandoz AG and Sandoz Pharmaceuticals AG. The claimants sought a pan-European injunction against the distribution of Sandoz’ aflibercept biosimilar, relying on both the Swiss designation and multiple foreign designations of a European patent. The case thus presented the Court with a textbook scenario for testing Switzerland’s credentials as a cross-border patent litigation forum.</p> <p class="MsoBodyText">The Court rose to the occasion, delivering clear guidance on two issues that matter for any cross-border patent strategy:</p>

Insights 03.08.2026

The EU AI Act: New prohibitions and transparency take effect and what is yet to come

The EU AI Act: New prohibitions and transparency take effect and what is…

<p class="MsoBodyText">Regulation (EU) 2024/1689 of 13 June 2024 (“<strong>EU</strong> <strong>AI Act</strong>”)&nbsp;general application date of <em>2 August 2026</em> has arrived, but the regulatory landscape looks materially different from the original plan.</p> <p class="MsoBodyText">The amending Regulation (EU) 2026/1744 (“<strong>AI Omnibus</strong>”)&nbsp;has deferred the core high-risk AI obligations to 2027, even 2028, while introducing a new prohibition on non-consensual intimate “deepfake” content and a labelling grace period for legacy generative AI systems. This Legal Insight maps the current compliance landscape for Swiss companies with EU market exposure, with a particular focus on implications for the banking and financial services sector.</p>

SEE ALL